Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.51 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210198 | 1.00 | ATR (0.51) | ATRATRIPPIK3CAMTORKCNH2 | |
| SCHEMBL6520863 | 1.00 | ATR (0.51) | ATRATRIPPIK3CAMTORKCNH2 | |
| SCHEMBL6524143 | 0.91 | PIK3R1 (0.44) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL2492774 | 0.91 | PIK3R1 (0.44) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL2488472 | 0.91 | PIK3CA (0.47) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL2487547 | 0.91 | PIK3CA (0.47) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL6525673 | 0.91 | PIK3R1 (0.43) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL2488469 | 0.91 | PIK3CA (0.47) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL6525675 | 0.91 | PIK3R1 (0.43) | ATRATRIPPIK3CAMTORPIK3R1 | |
| SCHEMBL22790318 | 0.89 | ATR (0.49) | ATRATRIPPIK3CAMTORKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ATR 2253/4885ATRIP 3336/4885PIK3CA 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.